Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

FDA clears Inhibikase IkT-001 Phase II trial to treat JCV infection in multiple sclerosis patients

Inhibikase Therapeutics, Inc., an emerging leader in infectious disease, announced today that it has received FDA clearance to commence a Phase II proof-of-concept trial for its lead compound IkT-001. IkT-001, a host-directed kinase inhibitor, is intended to clear JC polyomavirus (JCV) infection, the causative agent of Progressive Multifocal Leukoencephalopathy (PML).

17 Aug 2011

Study finds broadest immune response from LAIV nasal spray vaccines for children

Children younger than 3 years old receive the same protective antibody response from the recommended two doses of licensed seasonal influenza vaccines regardless of whether the two doses are injected by needle, inhaled through a nasal spray or provided through one dose of each in any order, according to researchers funded by the National Institutes of Health.

17 Aug 2011

Patrys product shows activity in multiple myeloma cancer cells

Patrys Limited today announced the results of preclinical work conducted at The University Hospital of Würzburg showing the activity of one of Patrys’ products in multiple myeloma.

16 Aug 2011

Human Genome Sciences, 4-Antibody sign collaboration agreement

4-Antibody AG today announced the signing of a collaboration agreement with Human Genome Sciences (HGS) to discover and develop fully human therapeutic antibodies.

16 Aug 2011

Bristol-Myers Squibb, BAC to develop CaptureSelect ligands for purification of Adnectins

BAC BV, the leading provider of antibody based affinity purification technology, has announced a collaboration with Bristol-Myers Squibb Company to generate CaptureSelect affinity ligands for applications in the purification and analysis of a proprietary type of targeted biologic, called Adnectins.

16 Aug 2011

Toclizumab for juvenile rheumatoid arthritis

The arthritis drug Toclizumab could be a boon for hundreds of children suffering from severe arthritis. It has been re-launched in children after being already licensed for the treatment of adults. At least two thirds of children taking tocizilumab have been able to return to a normal life, after many were bedridden or forced into wheelchairs by the disease, the clinical studies reveal.

16 Aug 2011

Amorfix provides update on cancer therapeutic antibody programs

Amorfix Life Sciences Ltd., a product development company focused on diagnostics and therapeutics for misfolded protein diseases, provides an update on its cancer therapeutic antibody programs.

12 Aug 2011

New technique can help develop HIV vaccines

Researchers have traced in detail how certain powerful HIV neutralizing antibodies evolve, a finding that generates vital clues to guide the design of a preventive HIV vaccine, according to a study appearing in Science Express this week.

12 Aug 2011

Alternatives needed to inaccurate blood tests used to diagnose active TB

A guest post in PLoS Medicine's "Speaking of Medicine" blog, written by tuberculosis (TB) researchers Madhukar Pai of McGill University, David Dowdy of the Johns Hopkins Bloomberg School of Public Health, and Karen Steingart of the University of Washington School of Public Health, examines the medical, public health and economic consequences of the widespread use of inaccurate antibody-based serological diagnostic tests for active TB.

12 Aug 2011

Commercial blood serum antibody tests cost-effective, not accurate for active TB

Commercial blood serum antibody tests—widely used in India and other developing countries to diagnose active tuberculosis—are not accurate or cost-effective, according to an analysis by researchers at the Johns Hopkins Bloomberg School of Public Health, the University of Washington School of Public Health and McGill University.

11 Aug 2011

New findings on human brain's photosensitivity

Valkee, inventor of the world's first bright-light headset, and scientists from the University of Oulu will present new findings on human brain's photosensitivity at the Scandinavian Physiology Society Annual Meeting 2011, August 12-14.

11 Aug 2011

Pfizer, UC San Diego sign research agreement to drive innovation in drug discovery

In an innovative collaboration designed to speed the process of drug discovery, Pfizer, Inc. and the University of California, San Diego Health Sciences announced today that UC San Diego has joined the ranks of other top-tier life science research institutions across the country as part of Pfizer's Centers for Therapeutic Innovation.

9 Aug 2011

Engineered T cells can eradicate deadly human ovarian cancer in immune-deficient mice

In a recent issue of Cancer Research, Daniel J. Powell, Jr., PhD, a research assistant professor of Pathology and Laboratory Medicine and Obstetrics and Gynecology at the Perelman School of Medicine at the University of Pennsylvania, showed for the first time that engineered human T cells can eradicate deadly human ovarian cancer in immune-deficient mice.

9 Aug 2011

Study finds key influential factors linked with risk of allergies in babies

Prenatal pet exposure, a mother's delivery mode and race are influential factors in a child's risk of developing allergies by age 2, according to a Henry Ford Hospital study.

9 Aug 2011

Gilead to acquire Genentech's OCP facility, other process development assets

Gilead Sciences, Inc. today announced that the company has signed a definitive agreement under which Gilead will purchase a clinical biologics manufacturing facility and certain process development assets located in Oceanside, California from Genentech, a member of the Roche Group.

9 Aug 2011

Idera second quarter net loss increases to $6.3 million

Idera Pharmaceuticals, Inc. today reported financial results for the second quarter ended June 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-Like receptors (TLRs).

5 Aug 2011

Takeda, Amylin discontinue pramlintide/metreleptin development program for obesity

Amylin Pharmaceuticals, Inc. and Takeda Pharmaceutical Company Limited today announced that they are discontinuing development of pramlintide/metreleptin, an investigational combination therapy for the treatment of obesity that comprises pramlintide, an analog of the natural hormone amylin, and metreleptin, an analog of the natural hormone leptin.

5 Aug 2011